Literature DB >> 14508387

Phenotypic and genotypic analysis of thiopurine s-methyltransferase polymorphism in the bulgarian population.

Dessislava Indjova1, Srebrena Atanasova, Maria Shipkova, Victor W Armstrong, Michael Oellerich, Dobrin Svinarov.   

Abstract

Genetic polymorphism of TPMT activity is an important factor responsible for large individual differences in thiopurine toxicity and therapeutic efficacy. The aim of this study was to determine the distribution of TPMT activity as well as the types and frequencies of mutant alleles in a Bulgarian population sample. TPMT activity was measured in 313 Bulgarians, using an established HPLC procedure. All individuals with TPMT activity less than 12.0 nmol/(mL Ery.h) (n = 76) were additionally genotyped using a color multiplex hybridization assay. The samples were tested for TPMT*2, *3A, *3B, *3C, *3D, *4, and *6 mutant alleles. TPMT activities varied from 1.1 to 24.0 nmol/(mL Ery.h) [mean 14.2 +/- 3.2 nmol/(mL Ery.h)]: 92.3% of the individuals investigated had high TPMT activity [>10 nmol/(mL Ery. h)], whereas 7.4% were intermediate [2.8-10 nmol/(mL Ery.h)], and 0.3% were low metabolizers [< 2.8 nmol/(mL Ery.h)]. A significant gender-related difference in TPMT activity (P = 0.02) was observed with 6.2% higher values in men than in women. There was no significant correlation between age and enzyme activity (r = 0.06, P = 0.27). Genotype analysis revealed three mutant TPMT alleles: 2, 3A, and 3C. The frequency of these alleles among the TPMT-deficient individuals was 2.17%, 30.4%, and 2.17%, respectively. These data show a similar distribution of TPMT activity among the Bulgarian population investigated as in most other white populations with the frequency of intermediate metabolizers being somewhat lower (7.4% versus approximately 11%) in the Bulgarians. The most common variant allele was TPMT-3A, as in other white populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508387     DOI: 10.1097/00007691-200310000-00013

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

Review 1.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 2.  Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-06-09

3.  Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review.

Authors:  Lilla M Roy; Richard M Zur; Elizabeth Uleryk; Chris Carew; Shinya Ito; Wendy J Ungar
Journal:  Pharmacogenomics       Date:  2016-03-29       Impact factor: 2.533

4.  Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.

Authors:  Ana Teresa P Carvalho; Barbara C Esberard; Renata S B Fróes; Davy C M Rapozo; Ana B Grinman; Tatiana A Simão; Juliana C V C Santos; Antonio José V Carneiro; Luis Felipe Ribeiro-Pinto; Heitor S P de Souza
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

5.  Thiopurine S-methyltransferase gene (TMPT) polymorphisms in a Mexican population of healthy individuals and leukemic patients.

Authors:  Lucia Taja-Chayeb; Silvia Vidal-Millán; Olga Gutiérrez; Patricia Ostrosky-Wegman; Alfonso Dueñas-González; Myrna Candelaria
Journal:  Med Oncol       Date:  2007-09-06       Impact factor: 3.064

Review 6.  Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.

Authors:  Vid Mlakar; Patricia Huezo-Diaz Curtis; Chakradhara Rao Satyanarayana Uppugunduri; Maja Krajinovic; Marc Ansari
Journal:  Int J Mol Sci       Date:  2016-09-08       Impact factor: 5.923

7.  The Association Between Azathioprine Genetic Polymorphisms, Clinical Efficacy and Adverse Drug Reactions Among Egyptian Patients with Autoimmune Diseases.

Authors:  Nermeen Abuelsoud; Hala Fayed; Engy Elkateeb
Journal:  Pharmgenomics Pers Med       Date:  2021-02-02

8.  Pharmacogenomic assessment of Mexican and Peruvian populations.

Authors:  Sharon Marsh; Cristi R King; Derek J Van Booven; Jane Y Revollo; Robert H Gilman; Howard L McLeod
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

Review 9.  Clinical pharmacology and pharmacogenetics of thiopurines.

Authors:  Srikumar Sahasranaman; Danny Howard; Sandip Roy
Journal:  Eur J Clin Pharmacol       Date:  2008-05-28       Impact factor: 3.064

10.  Polymorphisms of the thiopurine S-methyltransferase gene among the Libyan population.

Authors:  Hamza Ben Zeglam; Abdrazak Benhamer; Adel Aboud; Haitem Rtemi; Meftah Mattardi; Saleh Suleiman Saleh; Abdullah Bashein; Nabil Enattah
Journal:  Libyan J Med       Date:  2015-03-26       Impact factor: 1.743

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.